Sinonasal Outcome Test-22
Also known as: SNOT-22, SNOT
The SNOT-22 is a 22-item disease-specific quality-of-life questionnaire designed to assess sino-nasal symptoms and their functional impact on patients with chronic rhinosinusitis, nasal polyposis, and allied conditions. Developed by Hopkins and colleagues at King's College London in 2009, it has become the most widely used instrument for measuring sino-nasal disease burden in clinical trials and rhinological practice. The SNOT-22 provides rapid, patient-centered assessment of both nasal-specific symptoms (congestion, drainage, sneezing) and general health impacts (sleep, headache, concentration).
Key highlights
- Disease-specific: All 22 items directly address sino-nasal symptoms and disease-relevant impacts; no generic filler items
- Psychometrically rigorous: Demonstrates high internal consistency (Cronbach's α=0.95), strong test–retest reliability (ICC>0.9), and construct validity across multiple languages
- Well-defined MCID: 8.9-point threshold provides objective benchmark for clinical improvement, essential for surgical decision-making and trial design
- Rapid administration: 5–7 minute completion time facilitates routine clinic use; no specialist training required
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
The SNOT-22 is indicated for patients with chronic rhinosinusitis (CRS), nasal polyposis, allergic rhinitis, or other chronic sino-nasal conditions. It is the preferred instrument in rhinological clinical trials, pre–post surgical efficacy studies, and subspecialty rhinology clinics. The SNOT-22 is less useful for acute sinusitis (where symptoms fluctuate rapidly) or primary care screening (use simpler allergic rhinitis tools instead). It has also been adapted for use in non-sino-nasal conditions (e.g., cystic fibrosis-related sinus disease).
Strengths & limitations
- Disease-specific: All 22 items directly address sino-nasal symptoms and disease-relevant impacts; no generic filler items
- Psychometrically rigorous: Demonstrates high internal consistency (Cronbach's α=0.95), strong test–retest reliability (ICC>0.9), and construct validity across multiple languages
- Well-defined MCID: 8.9-point threshold provides objective benchmark for clinical improvement, essential for surgical decision-making and trial design
- Rapid administration: 5–7 minute completion time facilitates routine clinic use; no specialist training required
- Potential for ceiling/floor effects in mild disease or complete remission: Minimal symptoms may yield non-informative low scores with limited discrimination
- Item redundancy: Some overlapping content (e.g., multiple drainage-related items) limits statistical independence
- Limited scope in acute settings: 22-item length may be excessive for acute exacerbation assessment; shorter instruments may be preferable
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Is SNOT-22 suitable for acute sinusitis, or only chronic rhinosinusitis?
SNOT-22 is designed for chronic conditions; acute sinusitis is self-limited and symptoms resolve quickly. For acute exacerbation assessment, simpler symptom diaries or visual analog scales are preferable. Use SNOT-22 in acute exacerbations of chronic CRS or when assessing CRS baseline prior to acute worsening.
A patient improves by 6 points on SNOT-22; is this clinically meaningful?
A 6-point improvement falls below the MCID threshold of 8.9 points, suggesting non-significant change at the group level. However, individual patient perception matters; if the patient reports meaningful symptom relief, clinical judgment trumps the cutoff. Always integrate SNOT-22 with objective findings and patient satisfaction.
How do I score SNOT-22 if the patient skips items?
Missing item handling varies by study protocol. Typically, if <5% of items are missing, the patient's mean item score can impute the missing value(s). If >5% are missing, the questionnaire is considered incomplete. Modern digital versions often enforce item completion to avoid this issue.
Should I use SNOT-22 or RQLQ for allergic rhinitis?
SNOT-22 is better for chronic rhinosinusitis and nasal polyps. RQLQ (Rhinoconjunctivitis QoL Questionnaire) is more sensitive for allergic rhinitis with eye symptoms. Consider disease phenotype: if predominantly nasal/sinus, use SNOT-22; if allergic rhinitis with ocular involvement, consider RQLQ.
Sources
- 1.Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009). Psychometric validity of the 22-item Sinonasal Outcome Test. Clinical Otolaryngology, 34(5), 447-454.
- 2.Kennedy, J. L., Hubbard, M. A., Huyett, P., Patanavanich, S., Gould, H. M., & Köller, D. Y. (2012). Sino-Nasal Outcome Test (SNOT-22): A multicenter validation study. Rhinology, 50(4), 359-363.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). SNOT-22. ScholarGate. https://scholargate.app/pulmonology/sinonasal-outcome-test